Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-01-29
1994-08-23
Lee, Lester L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 19, 530330, 530331, A61K 3702, C07K 506, C07K 508, C07K 510
Patent
active
053408020
ABSTRACT:
Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.
REFERENCES:
patent: 4294825 (1981-10-01), Knoll et al.
patent: 4481138 (1984-11-01), Tachibana et al.
patent: 4490364 (1984-10-01), Rivier et al.
patent: 4618598 (1986-10-01), Conn
McLaughlin et al. "Effect of CCK Antibodies on Food Intake and Weight in Zuckerrats", Physiol. Behav, 34:227-282 (1985).
D. Horwell et al., J. Med. Chem. 30:725-732 (1987).
Brodie Mark S.
Chung John Y.-L.
Garvey David S.
Holladay Mark W.
May Paul D.
Abbott Laboratories
Crowley Steven R.
Elder Richard A.
Lee Lester L.
Weinstock Steven F.
LandOfFree
Peptide analog type-B CCK receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide analog type-B CCK receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide analog type-B CCK receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-503140